{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:43:14Z","timestamp":1777513394808,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>HER2-low populations constitute a heterogeneous group, and the cytotoxic anticancer agent efficacy based on HER2 status remains unclear. This study evaluated the clinicopathological features and outcomes of patients with advanced breast cancer showing HER2-low expression treated with eribulin or capecitabine, two treatment options after anthracycline and taxane treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively evaluated patients who were treated with eribulin or capecitabine between 2011 and 2015. HER2 status was evaluated according to the ASCO\/CAP guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No significant difference was observed in overall survival (OS; eribulin: hazard ratio [HR], 0.66; 95% CI 0.40\u20131.10; capecitabine: HR, 0.76; 95% CI 0.45\u20131.30) or progression-free survival (PFS; eribulin: HR, 1.13; 95% CI 0.72\u20131.78; capecitabine: HR, 0.90; 95% CI 0.56\u20131.44) between patients receiving eribulin (HER2-null: 35, HER2-low: 44) and those receiving capecitabine (HER2-null: 41, HER2-low: 33). Subgroup analysis revealed no significant differences in OS between the two groups in the hormone-positive and -negative populations for eribulin and capecitabine. HER2-null and HER2-low patients showed objective response rates (ORRs) of 22.5% and 9.1% (p\u2009=\u20090.09) overall, and 32.0% and 10.5% (p\u2009=\u20090.03), respectively, in hormone-positive cases among eribulin-treated patients. No response was observed in hormone-negative patients. Capecitabine treatment in HER2-null and HER2-low patients had overall ORRs of 26.8% and 15.2% (p\u2009=\u20090.23), respectively, with 27.3% and 16.1% (p\u2009=\u20090.28) for hormone-positive cases; and 25.0% and 0% (p\u2009=\u20091.0), respectively, for hormone-negative cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Eribulin and capecitabine sensitivity may vary based on HER2 expression in patients with HER2-low and HER2-null breast cancer. Prognosis was similar between the HER2-low and the HER2-null groups.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12282-024-01617-y","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:02:24Z","timestamp":1723633344000},"page":"1037-1045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0478-9427","authenticated-orcid":false,"given":"Rui","family":"Kitadai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-8575","authenticated-orcid":false,"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-9927","authenticated-orcid":false,"given":"Shu","family":"Yazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-7361","authenticated-orcid":false,"given":"Hitomi Sumiyoshi","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4751-6094","authenticated-orcid":false,"given":"Munehiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-4287","authenticated-orcid":false,"given":"Ayumi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shosuke","family":"Kita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-5510","authenticated-orcid":false,"given":"Yuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-4208","authenticated-orcid":false,"given":"Tadaaki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4600-9428","authenticated-orcid":false,"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0326-7555","authenticated-orcid":false,"given":"Emi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1229-5446","authenticated-orcid":false,"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-7611","authenticated-orcid":false,"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"1617_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","volume":"381","author":"DF Hayes","year":"2019","unstructured":"Hayes DF. HER2 and breast cancer \u2013 a phenomenal success story. N Engl J Med. 2019;381:1284\u20136. https:\/\/doi.org\/10.1056\/NEJMcibr1909386.","journal-title":"N Engl J Med"},{"key":"1617_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707\u201312. https:\/\/doi.org\/10.1126\/science.2470152.","journal-title":"Science"},{"key":"1617_CR3","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389:2415\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(16)32417-5.","journal-title":"Lancet"},{"key":"1617_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010.","journal-title":"Ann Oncol"},{"key":"1617_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/cancers13051015","volume":"13","author":"D Eiger","year":"2021","unstructured":"Eiger D, Agostinetto E, Sa\u00fade-Conde R, de Azambuja E. The exciting new field of HER2-low breast cancer treatment. Cancers (Basel). 2021;13:1015. https:\/\/doi.org\/10.3390\/cancers13051015.","journal-title":"Cancers (Basel)"},{"key":"1617_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101592","volume":"8","author":"C Molinelli","year":"2023","unstructured":"Molinelli C, Jacobs F, Agostinetto E, Nader-Marta G, Ceppi M, Bruzzone M, et al. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis. ESMO Open. 2023;8: 101592. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101592.","journal-title":"ESMO Open"},{"key":"1617_CR7","doi-asserted-by":"publisher","first-page":"1157789","DOI":"10.3389\/fonc.2023.1157789","volume":"13","author":"T Sanomachi","year":"2023","unstructured":"Sanomachi T, Okuma HS, Kitadai R, Kawachi A, Yazaki S, Tokura M, et al. Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer. Front Oncol. 2023;13:1157789. https:\/\/doi.org\/10.3389\/fonc.2023.1157789.","journal-title":"Front Oncol"},{"key":"1617_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, Par\u00e9 L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7:1. https:\/\/doi.org\/10.1038\/s41523-020-00208-2.","journal-title":"NPJ Breast Cancer"},{"key":"1617_CR9","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38:1951\u201362. https:\/\/doi.org\/10.1200\/JCO.19.02488.","journal-title":"J Clin Oncol"},{"key":"1617_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1617_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33:594\u2013601. https:\/\/doi.org\/10.1200\/JCO.2013.52.4892.","journal-title":"J Clin Oncol"},{"key":"1617_CR12","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6.","journal-title":"Lancet"},{"key":"1617_CR13","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","volume":"25","author":"L Harris","year":"2007","unstructured":"Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287\u2013312. https:\/\/doi.org\/10.1200\/JCO.2007.14.2364.","journal-title":"J Clin Oncol"},{"key":"1617_CR14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1200\/JCO.2013.54.2530","volume":"32","author":"K Lambein","year":"2014","unstructured":"Lambein K, Van Bockstal M, Denys H, Libbrecht L. 2013 update of the American Society of Clinical Oncology\/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers. J Clin Oncol. 2014;32:1856\u20137. https:\/\/doi.org\/10.1200\/JCO.2013.54.2530.","journal-title":"J Clin Oncol"},{"key":"1617_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1617_CR16","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(21)00301-6.","journal-title":"Lancet Oncol"},{"key":"1617_CR17","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","volume":"9","author":"DS Peiffer","year":"2023","unstructured":"Peiffer DS, Zhao F, Chen N, Hahn OM, Nanda R, Olopade OI, et al. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol. 2023;9:500\u201310. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7476.","journal-title":"JAMA Oncol"},{"key":"1617_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3322\/caac.21271","volume":"65","author":"B Daly","year":"2015","unstructured":"Daly B, Olopade OI. A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015;65:221\u201338. https:\/\/doi.org\/10.3322\/caac.21271.","journal-title":"CA Cancer J Clin"},{"key":"1617_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2021.12.022","volume":"163","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Gandini S, Nicol\u00f2 E, Trillo P, Giugliano F, Zagami P, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer. 2022;163:35\u201343. https:\/\/doi.org\/10.1016\/j.ejca.2021.12.022.","journal-title":"Eur J Cancer"},{"key":"1617_CR20","doi-asserted-by":"publisher","first-page":"1270453","DOI":"10.3389\/fendo.2023.1270453","volume":"14","author":"S You","year":"2023","unstructured":"You S, Gong C, Li Y, Xie Y, Li Y, Zhao Y, et al. Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive\/HER2-low metastatic breast cancer. Front Endocrinol (Lausanne). 2023;14:1270453. https:\/\/doi.org\/10.3389\/fendo.2023.1270453.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01617-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-024-01617-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-024-01617-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T11:10:47Z","timestamp":1729249847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-024-01617-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1617"],"URL":"https:\/\/doi.org\/10.1007\/s12282-024-01617-y","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T. Nishikawa has a speakers\u2019 bureau for Chugai Pharma, Eisai, Genmab, MSD, Roche Diagnostics, Sanofi, and Takeda and institutional research funding from AstraZeneca and Daiichi-Sankyo. K. Sudo reports receiving grants from Daiichi-Sankyo, AstraZeneca, Amgen, PRA Health Sciences, NanoCarrier, Takeda, Merck, and Gilead. He also reports receiving honoraria for speakers' bureaus and manuscript writing from AstraZeneca, Eisai, Bayer Yakuhin, Pfizer, Nihon Medi-Physics, and MSD. M. Yoshida reports receiving consulting fees from Lilly Japan and Roche Japan. He also reports receiving honoraria for speakers' bureaus and manuscript writing from Agilent technologies, Chugai Pharma, Ono Yakuhin, MSD, and Daiichi-Sankyo. K. Yonemori has a speakers\u2019 bureau for Honorarim for lecture: Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR pharma, MSD, Boeringer Ingelheim, Ono, Daiichi-Sankyo, Bayer, Jansen, Asteras, Bristol Myers Squibb, and Sanofi. He is an Advisory board for Eisai, Astra Zeneca, Sanofi, Genmab, Gliad, OncXerna, Takeda, Novartis, MSD, and Henlius. He reports receiving research grants from MSD, Daiichi-Sankyo, Merk Biopharma, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boeringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe. He also reports receiving honoraria for lectures, presentations, and speakers' bureaus for Pfizer, Eisai, AstraZeneca, Eli lilly, Takeda, Chugai, MSD, FujiFilm Pharma, Bayer, Asteras, Boehringer Ingelheim, Daiichi-Sankyo, PDR pharma, and Sanofi. He is also a principal investigator for MSD, Daiichi-Sankyo, AstraZeneca, Taiho, Merk Biopharma Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boeringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the National Cancer Center (Tokyo, Japan) [No. 2014-092]. This study was conducted in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived by the Institutional Review Board owing to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}